Article Versions Notes

Salzmann M, Wald A, Stege H, Loquai C, Zimmer L, Hayani KM, Heinzerling L, Gutzmer R, Enk AH, Hassel JC. Tolerability of BRAF and MEK Inhibitors for Metastasized Melanoma after Intra-Class Switch: A Multicenter, Retrospective Study. Cancers. 2023; 15(5):1426. https://doi.org/10.3390/cancers15051426

Salzmann, Martin, Alexander Wald, Henner Stege, Carmen Loquai, Lisa Zimmer, Kinan M. Hayani, Lucie Heinzerling, Ralf Gutzmer, Alexander H. Enk, and Jessica C. Hassel. 2023. "Tolerability of BRAF and MEK Inhibitors for Metastasized Melanoma after Intra-Class Switch: A Multicenter, Retrospective Study" Cancers 15, no. 5: 1426. https://doi.org/10.3390/cancers15051426

Salzmann, M., Wald, A., Stege, H., Loquai, C., Zimmer, L., Hayani, K. M., Heinzerling, L., Gutzmer, R., Enk, A. H., & Hassel, J. C. (2023). Tolerability of BRAF and MEK Inhibitors for Metastasized Melanoma after Intra-Class Switch: A Multicenter, Retrospective Study. Cancers, 15(5), 1426. https://doi.org/10.3390/cancers15051426